Dominantly Inherited Alzheimer Network: Biomarker Core
显性遗传阿尔茨海默病网络:生物标志物核心
基本信息
- 批准号:10462560
- 负责人:
- 金额:$ 40.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease riskAmyloid beta-42Biological AssayBiological MarkersBrainClinicalClinical TrialsCognitive deficitsCross-Sectional StudiesDataDementiaDetectionDevelopmentDiseaseDisease MarkerEnrollmentEvaluationFamilyFundingFutureGoalsImmunoassayImpaired cognitionIndividualInheritedLeftLiquid substanceMeasuresModelingMonitorMutationNeurofibrillary TanglesNeuronal InjuryObservational StudyParticipantPatient RecruitmentsPenetrancePerformancePersonsPharmaceutical PreparationsPlasmaPositioning AttributeProcessPublic HealthQuality ControlReproducibilityResearch PersonnelRiskRunningSamplingSenile PlaquesSymptomsTestingTimearmautosomal dominant Alzheimer&aposs diseasebiobankcohortdata handlingdata qualitydesignelectronic datahigh riskimprovedin-vitro diagnosticsinsightlaboratory experiencelongitudinal analysismutation carriernext generationpre-clinicalpreventresearch clinical testingspecific biomarkerssuccesstau Proteinstherapy development
项目摘要
Core E: Biomarker PROJECT SUMMARY/ABSTRACT
Alzheimer disease (AD) will become a public health crisis in the very near future if left untreated. There are
currently no proven treatments that delay the onset or prevent the progression of AD, although several
promising candidates are being tested. During therapy development, it will be critical to have biomarkers that
identify individuals at high risk for AD in order to target them for clinical trials and to monitor therapy.
Autosomal-dominant AD (ADAD) accounts for a very small proportion of all AD cases (<1%) but the
neuropathologic hallmarks and clinical features are similar to the more common sporadic, late-onset form
(LOAD). Individuals possessing AD mutations are destined to develop the disease and at a relatively
predictable age, thus providing a unique cohort in which to investigate the trajectories/timing of underlying
AD pathologies, especially as one transitions from the preclinical/asymptomatic to the symptomatic stage.
During the initial funding periods of DIAN, the Biomarker Core analyzed CSF and plasma samples obtained
from participants at baseline, including mutation carriers (MC) and non-carriers (NC) that fell along a wide
spectrum of estimated years to symptom onset (EYO). Cross-sectional analyses demonstrated elevated
CSF tau and ptau181, markers of neuronal injury and/or neurofibrillary tangles, ~10-20 years prior to the
estimated age of symptom onset (EYO -10 to -20). Low levels of CSF Aβ1-42, a marker of β-amyloid
plaques, were first observed in MC at ~EYO -10, but levels appeared to start to decline much earlier (~EYO
-25) from levels initially higher than NC. Interestingly, more recent analyses of longitudinal samples revealed
a slowing of the increase in CSF tTau and an actual reduction in pTau levels in symptomatic MC (EYO>0) over
time, perhaps reflecting its sequestration into tangles in the brain as is observed for CSF Aβ1-42 during the
development of plaques. These results emphasize the importance of longitudinal, within-person assessment
when modeling biomarker trajectories across the natural course of the disease. What remains to be determined
is the trajectory of biomarker changes within MC as they progress from the asymptomatic to the symptomatic
stages. Such information will be critical for the design and evaluation of clinical trials intended to prevent the
onset of cognitive decline in individuals at risk for developing dementia due to AD.
In the present application, we will build upon our success through four Specific Aims: Aim 1) Maintain and
grow the biorepository of DIAN CSF and plasma samples and coordinate the distribution of samples to
qualified investigators for approved scientific studies; Aim 2) Obtain measures of established biomarker
analytes in CSF (Aβ1-40, Aβ1-42, t-Tau, p-Tau181) using the next generation, high-performance Lumipulse®
automated assay platform in order to support the aims of the DIAN cores and projects; Aim 3) Maintain 21
C.F.R. § 11 compliance for all Biomarker Core functions involving electronic data; and Aim 4) Perform quality
control evaluation of CSF biomarker assay rigor (precision and accuracy) and reproducibility.
核心E:生物标志物项目总结/摘要
阿尔茨海默病(AD)如果不及时治疗,将在不久的将来成为一个公共卫生危机。有
目前还没有经过证实的治疗方法可以延迟AD的发作或预防AD的进展,尽管有几种治疗方法,
有希望的候选人正在接受考验。在治疗开发过程中,关键是要有生物标志物,
识别AD高危个体,以便针对他们进行临床试验并监测治疗。
常染色体显性AD(ADAD)占所有AD病例的比例很小(<1%),但
神经病理学特征和临床特征与更常见的散发性迟发性形式相似
(加载)。具有AD突变的个体注定会发展这种疾病,并且在相对较低的发病率下,
可预测的年龄,从而提供一个独特的队列来研究潜在的轨迹/时间
AD病理,尤其是从临床前/无症状阶段过渡到症状阶段。
在DIAN的最初资助期间,生物标志物核心分析了获得的CSF和血浆样本,
从基线的参与者,包括突变携带者(MC)和非携带者(NC),下降沿着广泛
症状发作估计年数谱(EYO)。横断面分析显示,
CSF tau和ptau181是神经元损伤和/或神经元缠结的标志物,在神经元损伤前约10 - 20年,
症状发作的估计年龄(EYO-10至-20)。CSF A β 1 - 42水平低,是β淀粉样蛋白的标志物
在~EYO-10时首次在MC中观察到斑块,但水平似乎开始下降要早得多(~EYO
-25)从最初高于NC的水平。有趣的是,最近对纵向样本的分析显示,
在症状性MC(EYO> 0)中,CSF tTau增加的减缓和pTau水平的实际降低超过
时间,可能反映了其在脑中的缠结中的隔离,如在治疗期间观察到的CSF A β 1 - 42。
斑块的发展。这些结果强调了纵向的、个人内部评估的重要性
在疾病的自然过程中模拟生物标志物轨迹时。尚待确定的是
是MC从无症状发展到有症状时生物标志物变化的轨迹
阶段这些信息对于设计和评价旨在预防疾病的临床试验至关重要。
在由于AD而具有发展痴呆风险的个体中认知下降的开始。
在本申请中,我们将通过四个具体目标来建立我们的成功:目标1)保持和
培养DIAN CSF和血浆样本的生物储存库,并协调样本的分配,
获得批准的科学研究的合格研究者;目的2)获得已建立的生物标志物的测量值
使用下一代高性能Lumipulse®检测CSF中的分析物(A β 1 - 40、A β 1 - 42、t-Tau、p-Tau181)
自动化分析平台,以支持DIAN核心和项目的目标;目标3)维护21
C.F.R.§ 11涉及电子数据的所有生物标志物核心功能的合规性;以及目标4)执行质量
CSF生物标志物测定严格性(精密度和准确度)和再现性的对照评价。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anne Fagan其他文献
Anne Fagan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anne Fagan', 18)}}的其他基金
Dominantly Inherited Alzheimer Network: Project 3
显性遗传阿尔茨海默病网络:项目 3
- 批准号:
10225490 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Project 3
显性遗传阿尔茨海默病网络:项目 3
- 批准号:
10665750 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Biomarker Core
显性遗传阿尔茨海默病网络:生物标志物核心
- 批准号:
10665736 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Biomarker Core
显性遗传阿尔茨海默病网络:生物标志物核心
- 批准号:
10225482 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Project 3
显性遗传阿尔茨海默病网络:项目 3
- 批准号:
10462567 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Biomarker Core
显性遗传阿尔茨海默病网络:生物标志物核心
- 批准号:
10017832 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
Dominantly Inherited Alzheimer Network: Project 3
显性遗传阿尔茨海默病网络:项目 3
- 批准号:
10017847 - 财政年份:2008
- 资助金额:
$ 40.93万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 40.93万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 40.93万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 40.93万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 40.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 40.93万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 40.93万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 40.93万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 40.93万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 40.93万 - 项目类别:
Miscellaneous Programs